Expert Interview
Discussing the data from the CARTITUDE-4 Trial of Legend's CARVYKTI (ciltacabtagene autoleucel) in multiple myeloma
Ticker(s): LEGNInstitution: Washington University St. Louis
- Professor Department of Medicine Oncology Division Bone Marrow Transplantation & Leukemia at WUSTL
- Currently treats ~300 patients with multiple myeloma, 25 patients with AML, 10 patients with CMML, and ~15 patients per month with AL Amyloidosis.
- Clinical research focus on strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
CARVYKTI is a BCMA-targeted CAR-T cell therapy. Can you explain how this mechanism of action contributes to its effectiveness in treating multiple myeloma?
The CARTITUDE-4 trial demonstrated a statistically significant and clinically meaningful improvement in overall survival with CARVYKTI. Could you provide more details on the survival benefits observed in this trial?
In the CARTITUDE-4 trial, CARVYKTI was compared to pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd). How did CARVYKTI perform in comparison to these regimens?
Added By: catalin_adminSafety results were consistent with the established profile of CARVYKTI, and no new safety signals were identified. What are the key safety considerations and adverse events associated with CARVYKTI treatment?
Added By: catalin_adminThe trial noted a numerically higher percentage of early deaths in the CARVYKTI arm compared to the control arm. Can you discuss the factors contributing to these early deaths and how they are being addressed?
Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are significant concerns with CAR-T therapies. How are these toxicities managed in patients receiving CARVYKTI?
CARVYKTI received FDA approval based on the data from the CARTITUDE-4 trial. What are the next steps in the regulatory process, and are there plans for expanding its indications?
Given the results from the CARTITUDE-4 trial, what future research and development plans does Legend Biotech have for CARVYKTI? Are there plans to investigate its use in other hematologic malignancies?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
